aXichem updates the status for its Feed Additive application in EU for aXiphen
aXichem AB (publ), which develops and markets natural analogue industrial chemicals, announces, that EFSA has published the minutes form the FEEDAP panel on 26–28 September 2023. In the meeting the Panel endorsed the opinion of EFSA’s risk assessment, and it will be considered for written adoption after the outcome of the public consultation is addressed. This means the next step is for the public consultation to be finalized on the 16th of October and, if no comments are received from the public, EFSA’s scientific opinion will be prepared for publication. The final step is for the EU to formulate the regulations for the use of phenylcapsaicin and publish these in The Official Journal of the European Union. When the regulation is published, the product is formally approved. All information about the application and the process is just as before available at Open EFSA .
“I am pleased that we are proceeding. I will not speculate on when we can see a publication from EFSA or the EU. We have noted that the timings have surprised us before, but we are of course keen for it to happen as soon as possible. However, this is not a part of the process that we can influence. The fact that we have now come this far supports us in the initial market introduction of the product”, says Torsten Helsing, CEO of aXichem.
About phenylcapsaicin and aXiphen
The health benefits of chili, with its active ingredient capsaicin have been known for centuries. aXichem’s proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, bridged by a triple bond. The result is an innovative natural analogue capsaicin with high purity, where the pungency is greatly reduced.
Production tests and studies have proven the effectiveness of aXiphen® as an ingredient in poultry feed. A production test on on-floor salmonella prevalence, following the inclusion of 15 ppm phenylcapsaicin in a regular starter diet, was carried out in a full-scale commercial broiler production trial under farming conditions. The production test included about 1.6 million broiler chickens. The trial concluded that under the conditions of the test, the inclusion of 15 ppm phenylcapsaicin in broiler chicken feed statistically significantly reduced the number of farms with salmonella-positive floor boot swabs. The European model for production efficiency, EPEF, showed that breeding efficiency increased by 14% compared to traditional feeding.
This information is such that aXichem AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on 10 October 2023, at 09:15 CET.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Västra Hamnen Corporate Finance AB is Certified Adviser. More information is available at www.axichem.com.